GP
AMRX icon

Girard Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Girard Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,050
Closed -$23K – 267
2018
Q3 		$23K Buy
+1,050
New +$22.1K ﹤0.01% 576

Other funds holding AMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Girard Partners's AMRX Position: Q4 2018 in Review

Girard Partners sold out of Amneal Pharmaceuticals (AMRX) in Q4 2018, closing a stake of 1,050 shares — an estimated $23K sold.

Girard Partners first reported a position in AMRX in Q3 2018 and held it in 1 quarter. The position peaked at $23K in Q3 2018. 168 funds tracked by Wall St. Rank hold AMRX as of Q4 2018.

  • Girard Partners reported no remaining Amneal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Girard Partners sold 1,050 Amneal Pharmaceuticals shares in Q4 2018, an estimated $23K.
  • Girard Partners first reported a position in Amneal Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Girard Partners's Amneal Pharmaceuticals position peaked at $23K in Q3 2018.
  • 168 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.